7. TI glycosylated N6 h?emoglobin* or AB glycosylated N6 h?emoglobin* 8. TI glucos* N3 management* or AB glucos* N3 management* 9. #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 10. MM "Diabetes Mellitus, Non-Insulin-Dependent" 11. TX Diabetes Complications 12. TX MODY or NIDDM or T2DM 13. TX non insulin* depend* or noninsulin* depend* or noninsulin?depend* or non insulin?depend 14. TX diabet* AND (typ* 2 or typ* II) 15. TX diabet* AND (keto*resist* or non*keto*) 16. TI (onset AND (late or adult* or matur* or slow or stabl*)) and TI diabet* 17. AB (onset N3 (late or adult* or matur* or slow or stabl*)) and AB diabet* 18. #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 19. MM "Diabetes Insipidus" 20. TX diabet* insipidus 21. #19 or #20 22. #18 NOT #21 23. #9 or #22 24. TI (control* AND (intensi* or tight or conventional* or regular or usual or routin* or standard)) or AB (control* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) 25. TI (therap* AND (intensi* or tight or conventional* or regular or usual or routin* or standard)) or AB (therap* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) 26. TI (treatment* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) or AB (treatment* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) 27. TI (intervention* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) or AB (intervention* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) 28. TI ( management* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) or AB (management* N3 (intensi* or tight or conventional* or regular or usual or routin* or standard)) 29. #24 or #25 or #26 or #27 or #28 30. #23 and #29 31. TX random* OR blind* OR placebo* OR group* 32. TX animal* NOT (animal* AND human*) 33. #31 NOT #32 34. #30 and #33
Appendix 2. Description of bias assessment
Risk of bias components based on the Cochrane risk of bias tool classification:
Sequence generation
 Low risk of bias, if the allocation sequence was generated by a computer or a random number table or similar.  Uncertain risk of bias, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.  High risk of bias, if a system involving dates, names, or admittance number was used for the allocation of patients (quasi-randomised). Such trials were not found, but would have been excluded.
Allocation concealment
 Low risk of bias, if the allocation of patients involved a central independent unit, on-site locked computer, or consecutively numbered sealed envelopes.  Uncertain risk of bias, if the trial was described as randomised, but the method used to conceal the allocation was not described.  High risk of bias, if the allocation sequence was known to the investigators, who assigned participants or if the study was quasi-randomised. Such trials were not found, but would have been excluded.
Blinding
It was not possible to blind the health-care provider and patients in the treatment groups. Blinding was therefore considered adequate if the outcome assessors were blinded, although we were aware of the fact that even such trials may be subject to bias.  Low risk of bias, if the outcome assessors were blinded and the method of blinding was described.  Uncertain risk of bias, if the outcome assessors were blinded and the method of blinding was not described.  High risk of bias, if the outcome assessors were not blinded.
Incomplete data outcomes
 Low risk of bias, if it was clearly described if there were any postrandomisation drop-outs or withdrawals and the reason for these drop-outs was described.  Uncertain risk of bias, if it was not clear whether there were any drop-outs or withdrawals or if the reasons for these drop-outs were not clear.  High risk of bias, if the reasons for missing data were likely to be related to true outcomes; (1) 'as-treated' analysis were performed, (2) potentially inappropriate application of simple imputation, (3) potential for patients with missing outcomes to induce clinically relevant bias in effect estimate or effect size.
Selective outcome reporting  Low risk of bias, if all the pre-defined (primary and secondary) outcomes mentioned in the trial´s protocol or in the design article were reported and the reporting had been done in the pre-specified way.
 Uncertain risk of bias, if there was insufficient information to assess whether the risk of selective outcome reporting was present.  High risk of bias, if not all the pre-specified outcomes were reported or if the primary outcomes were changed or if some of the important outcomes were incompletely reported.
Other Bias
Sponsor bias  Low risk of bias, if the trial was unfunded or was not funded by an instrument or equipment or drug manufacturer.  Uncertain risk of bias, if the source of funding was not clear.  High risk of bias, if the trial was funded by an instrument or equipment or drug manufacturer.
Academic bias
 Low risk of bias, if the author of the trial had not conducted previous trials addressing the same interventions.  Uncertain risk of bias, if it was not clear if the author had conducted previous trials addressing the same interventions.  High risk of bias, if the author of the trial had conducted previous trials addressing the same interventions. Besides investigating each bias domain, we also evaluated the overall risk of bias. When sequence generation, allocation concealment, and blinding were judged adequately, the trial was classified as a trial with low-risk of bias. 
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